Approval · Notice of Compliance 31358 · 2023

LIPITOR: Notice of Compliance 31358

Issued August 2, 2023

A Notice of Compliance is Health Canada’s approval of a drug submission: a new drug, a new use or form, or a change to an approved one. The product itself is in the Drug Product Database, with its current status.

Notice number: 31358
Date: August 2, 2023
Company: BGP Pharma ULCEtobicoke, Ontario, Canada
Product type: Prescription Pharmaceutical
Submission: New Drug Submission (NDS)
Submission class: Admin
Reason: Administrative: Change in Product Ownership

Products in this notice

Brand	DIN	Status today
LIPITOR	02230711	Marketed
LIPITOR	02230713	Marketed
LIPITOR	02230714	Marketed
LIPITOR	02243097	Marketed

Medicinal ingredients

ATORVASTATIN CALCIUM 10 MG per TAB
ATORVASTATIN CALCIUM 20 MG per TAB
ATORVASTATIN CALCIUM 40 MG per TAB
ATORVASTATIN CALCIUM 80 MG per TAB